Steatotic liver diseases (SLD) have hepatic and extra-hepatic consequences. SLD includes three major chronic liver diseases: Metabolic dysfunction–associated SLD (MASLD), Metabolic dysfunction–associated alcohol-related liver disease (MetALD), and Alcohol-related liver disease (ALD). An association between SLD with risk of T2D, a major cancer risk factor, has been shown in some studies, but there is a paucity of data from large, prospective cohort studies. Moreover, potential syndemic interactions with socioeconomic position (SEP) have not been well studied.
Desta et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: